Michelle Cerdán earned her degree in Biology from the University of Navarra in 2020. Three years later, in 2023, she embarked on her PhD studies at the same institution, dedicating her research to the exploration of yeast-based probiotics and postbiotics. Since then, she has been actively engaged in advancing this field, focusing on the potential health benefits, applications, and mechanisms of action of these microorganisms. Her work aims to contribute to a deeper understanding of their role in human and animal health, paving the way for innovative biotechnological developments. Through her research, she seeks to uncover new insights that could lead to improved probiotic formulations and novel therapeutic approaches.

Josune Salvador received her Degree in Pharmacy and Human Nutrition and Dietetic from the University of Navarra, Spain, in 2020 and 2022 respectively. She started her PhD in the same University in 2023 and to this day continues to focus on the study of the development of a multivalent vaccine against Shigella flexneri and ETEC. Her research topics mainly include vaccines against infectious diseases, ETEC, heat-labile toxin (LT), Shigella flexneri and probiotic and postbiotic products.

Ana Villegas earned her degree in Biochemistry from the University of Navarra in 2024. During her studies, she focused her research project on the development of yeast-based probiotic and postbiotic products, working in collaboration with the university’s Microbiology Department. Her research aimed to explore the potential applications of these microorganisms in health and biotechnology, contributing to advancements in the field. Through this collaboration, she gained hands-on experience in microbiological techniques, formulation processes, and the evaluation of probiotic efficacy.

Ana Ceniceros obtained her Biology and Biochemistry degrees from the University of Navarra. Later, she moved to Groningen, The Netherlands, where she obtained her PhD degree at the University of Groningen "Bacterial natural products", searching for novel antibiotics in Streptomyces and Rhodococcus. After getting her PhD, she moved to Oviedo where she worked as a postdoctoral researcher at the University of Oviedo, focusing her research on antitumor compounds produced by the genus Streptomyces. Then she moved to the pharmaceutical company 3P Biopharmaceuticals, where she worked in the quality control department. Currently, she works at LEV2050 where now she occupies the position of R&D manager.

David García Yoldi earned his Bachelor’s degree in Pharmacy from the University of Navarra (1994-1999) and later completed a PhD in Molecular and Cellular Biology (2003-2008). His research focused on genetic differences in Brucella genes, developing molecular typing techniques, and using MLVA for epidemiological studies. In 2010, he founded LEV2050, a company specializing in industrial microbiology and the development of microorganisms to optimize food industry processes. In addition to having an RD team specialised in microbiology, the company focuses on the design and manufacture of patented bioreactors and culture media. In this field, he has authored 11 inventions, patents, and models.

Yadira Pastor received her Degree in Biochemistry from the University of Navarra, Spain, in 2014, and obtained her PhD Degree in the same University in 2019. She worked as a Postdoctoral Researcher at Vaccine Research Institute, Paris, France (2020–2022). In 2022 she moved back to the University of Navarra and has worked since then as a Researcher and Associate Professor. Her research topics mainly include vaccines against infectious diseases, probiotic and postbiotic products and antibiotic resistance.

Carlos Gamazo graduated with a BSc. (Biology) from the University of Navarra, and subsequently carried out PhD research in the area of Microbiology. After completing his PhD on vaccination, he went on to work as a Post-doctoral Research Fellow in the Department of Immunology at Cornell University (New York) in the period 1986-88. Further, in 1991, he was a visiting professor in the Department of Immunology at the University of Madison-Wisconsin. In 1988, he was appointed as a Lecturer in Microbiology in the School of Medicine, University of Navarra, acting as Full Professor since 2004. His main area of research interest is in the development of vaccines, with a particular focus on antigen delivery systems as immunoadjuvants, as well as the role of probiotics and postbiotics in immune stimulation. He has authored more than one hundred and forty publications in peer-reviewed scientific journals (D index 52) and currently holds eight patents.